Key facts
- Notable investors include Biolocity, Crohn's & Colitis Foundation, Georgia Research Alliance, Orange Grove Bio.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Allonix Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Allonix Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Allonix Therapeutics
Developer of small-molecule drugs designed to treat ulcerative colitis. The company is researching a cell-signaling pathway involved in inflammation, cholesterol homeostasis, and cellular metabolism, enabling customers to receive localized steroid treatment.
- Sector
- Healthcare
- HQ
- Cincinnati, OH, United States
- Ownership
- Privately Held (backing)
Allonix Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allonix Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allonix Therapeutics in its N-PORT filings yet. We sweep new filings monthly.